Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Structure and Function of Platelets

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

Formation of the Platelet Plug

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

COVID-19 Disease and SARS-CoV-2 Vaccination in Patients with Cancer.

Archives of pharmacology and therapeutics·2021

Same author

Neoadjuvant Therapy (NAT) in Localized Pancreatic Cancer: Should We Do It and What Should We Do?

Journal of cellular signaling·2021

Same author

The Role of Olaparib in Metastatic Pancreatic Cancer.

Cancer medicine journal·2021

Same author

Association of Pharmacogenetics With Adverse Events of Fluorouracil/Capecitabine in Patients With Cancer.

JCO oncology practice·2021

Same author

Safety and Efficacy of s-MOX Regimen in Patients with Colorectal Cancer Who Developed Cardiotoxicity Following Fluoropyrimidine Administration: A Case Series.

Archives of medical case reports·2020

Same author

Lessons Learnt from COVID-19: How Can We Prepare for Another Pandemic?

Archives of cancer biology and therapy·2020

Search research articles

Related Experiment Video

Updated: Jun 17, 2026

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Platelet count less than SHARP: what does a case series reveal?

Expert Opinion on Drug Safety

|December 17, 2009

Summary

This summary is machine-generated.

Sorafenib offers a survival benefit for advanced hepatocellular carcinoma (HCC). This study shows sorafenib is safe for HCC patients with low platelet counts, previously excluded from trials.

More Related Videos

Routine Screening Method for Microparticles in Platelet Transfusions

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

Related Experiment Videos

Last Updated: Jun 17, 2026

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Routine Screening Method for Microparticles in Platelet Transfusions

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

Area of Science:

Hepatocellular Carcinoma (HCC) Research
Oncology Drug Efficacy
Liver Disease Management

Background:

Advanced hepatocellular carcinoma (HCC) lacks effective systemic treatments.
The SHARP study established sorafenib as a survival-prolonging therapy for HCC.
SHARP trial inclusion criteria excluded patients with platelet counts below 60,000/mm³.

Observation:

Thrombocytopenia is a common complication in chronic liver disease patients.
Three HCC patients with platelet counts < 60,000/mm³ were treated with sorafenib.
These patients tolerated sorafenib without complications.

Findings:

Sorafenib can be safely administered to HCC patients with thrombocytopenia.
This case series expands the known safety profile of sorafenib in HCC.
Successful treatment was observed in patients with low platelet counts.

Implications:

Sorafenib may be a viable treatment option for advanced HCC patients with thrombocytopenia.
Careful monitoring and informed consent are crucial for managing bleeding risks.
Further research is warranted to confirm safety and efficacy in this patient subgroup.